Introduction to Checkpoint Inhibitors

Slides:

Advertisements

Similar presentations

Advancing Care Forward in Squamous Cell Carcinoma of the Head and Neck

Advertisements

Pembrolizumab Drugbank ID :DB09037 Half life : 28 days.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

COMPLICATIONS OF IMMUNOTHERAPY IN THE HOSPITALIZED PATIENT Vivek Batra MD, Emma Weaver MD Division of Medical Oncology, Thomas Jefferson University, Philadelphia.

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

Clinical Trials in IBD.

The Immune System. The Immune System Adaptive Immune Response.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

T-Cell Exhaustion: Can We Overcome It in Cancer?

Effective Management of Psoriatic Arthritis: Tailoring Treatments

Advanced NSCLC Without Actionable Mutations

State of the Art in HCC: Immune Checkpoint Modulation

New Patient Journeys in Non-small cell lung cancer

Discussion Outline Cells of the Immune System.

Spotlight on Immuno-Oncology in Melanoma

Metastatic Renal Cell Carcinoma

The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer

Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.

The Nurse View: Overcoming Challenges Associated With Cancer Immunotherapy.

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Program Goals Introduction Case 1: A 44-Year-Old Woman.

Optimizing Management of Advanced Bladder Cancer

Checkpoint Inhibition

Best Practices in Metastatic Colorectal Cancer

The Nurse View: Top Ten Things to Know About Immune-Mediated Adverse Events.

Treating mRCC After Initial Antiangiogenic Therapy:

Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Genitourinary Tract.

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Immunotherapy for cSCC

Personalizing Management in the Care of Patients With Advanced Sarcoma

Evolving Concepts in the Management of Head and Neck Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

Advancing Patient Care in RA

Locally Advanced Lung Cancer

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

The Changing Field of Melanoma: Ipilimumab.

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

Optimizing Joint Health in Hemophilia

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Challenges and Opportunities

Preparing for Checkpoint Inhibitors in Breast Cancer

Novel Concepts in the Management of RCC

Debates and Dilemmas, Part 1

From Adjuvant to Metastatic in Melanoma

Clinical courses of patients.

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

Clinical Considerations in the Use of Checkpoint Inhibitors Breast Cancer.

A Pharmacist's Guide to Safety and Use of Immune Checkpoint Inhibitors

Moving Care Forward in Advanced Gastric Cancer

Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.

Current Status of Biomarkers for Immune Checkpoint Inhibitors

Immune Checkpoint Inhibitors in Lung Cancer

Combining Immunotherapy and Chemotherapy in NSCLC

The Nurse View.

The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Overview of irAEs. Management of Immune-Related Adverse Events for Patients Receiving Checkpoint Inhibitor Therapy.

Motor Fluctuations in PD

Presentation transcript:

Mitigating the Challenge of Immune-Related AEs in the Emergency Department

Introduction to Checkpoint Inhibitors

MOA of PD-1/PD-L1 Pathway

FDA-Approved Checkpoint Inhibitors

Checkpoint Inhibitors in Oncology

The Breadth of irAEs

Immune-Related AEs in the ED

Patient Evaluation for irAEs in the ED

Management of irAEs in the ED

Challenges of irAEs in the ED

Case 1: 42-Year-Old Woman With Advanced Melanoma

Case 1: Management of Colitis

Case 2: 68-Year-Old Man With Advanced Lung Cancer

Variety of Pneumonitis Presentations

Case 2: Management of Pneumonitis

Case 3: 57-Year-Old Woman With Renal Cell Carcinoma

Case 3: Management of Hypophysitis

Additional irAEs to Consider

Additional irAEs to Consider (cont)

Additional irAEs to Consider (cont)

Summary

Abbreviations

Abbreviations (cont)